A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
A lower dose slows the weight loss and allows you to eat more calories, reducing the biological stress and restoring ovarian signaling
Semaglutide is effective for weight loss in diabetics and nondiabetics, as it reduces appetite and cravings, controls blood glucose, improves glycemic control and promotes satiety and fullness
It varies among plans and can depend on your tax rate, but when using FSA or HSA funds, people save roughly 30 percent on average
Patients should be aware of warning signs that indicate potentially serious complications or the need for treatment adjustment